Takeda Pharmaceutical Co Ltd v. Qilu Pharmaceutical Hainan Co Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Qilu Pharmaceutical (Hainan) Co., Ltd. (China)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 1:26-cv-01633, D.N.J., 02/18/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Qilu develops, markets, and sells generic pharmaceutical products throughout the United States, including in the district, and intends for its accused generic product to be sold there.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's LIVTENCITY® (maribavir) tablets constitutes an act of infringement of six U.S. patents related to maribavir compositions, methods of use, and synthesis.
• Technical Context: The technology concerns maribavir, an orally available antiviral medication used for treating cytomegalovirus (CMV) infections, which are a significant cause of morbidity and mortality in post-transplant patients.
• Key Procedural History: This is a Hatch-Waxman action triggered by Defendant Qilu's submission of ANDA No. 221142 with a Paragraph IV Certification, asserting that its generic product would not infringe the patents-in-suit or that the patents are invalid. Plaintiff received notice of this filing via a letter dated January 9, 2026.

Case Timeline

Date	Event
2010-10-28	Earliest Priority Date for '632 and '169 Patents
2021-11-19	Earliest Priority Date for '989, '907, and '170 Patents
2022-10-12	Earliest Priority Date for '940 Patent
2023-06-27	U.S. Patent No. 11,684,632 Issues
2025-02-04	U.S. Patent No. 12,213,989 Issues
2025-05-13	U.S. Patent No. 12,295,940 Issues
2025-10-07	U.S. Patent No. 12,433,907 Issues
2025-10-21	U.S. Patent No. 12,447,169 Issues
2025-10-21	U.S. Patent No. 12,447,170 Issues
2026-01-09	Date of Defendant's Notice Letter to Plaintiff
2026-02-18	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632

• Patent Identification: U.S. Patent No. 11,684,632 (Maribavir Isomers, Compositions, Methods of Making and Methods of Using), issued June 27, 2023.
• The Invention Explained:
  • Problem Addressed: The patent's background section describes the unexpected discovery that maribavir, an antiviral drug, may isomerize in vivo into different molecular forms (constitutional isomers or stereoisomers) that do not necessarily have the same biological activity '632 Patent, col. 1:56-61 This isomerization is believed to have diluted the drug's effective concentration and contributed to the failure of a prior Phase 3 clinical trial, particularly when the drug was administered with food '632 Patent, col. 2:20-56
  • The Patented Solution: The invention claims to enhance maribavir's therapeutic efficacy by providing methods to mitigate this in vivo isomerization '632 Patent, col. 3:1-7 The patented solutions include specific methods of dosing the drug (e.g., under fasted conditions), particular formulations, and methods of using the maribavir isomers themselves '632 Patent, col. 3:50-64 The chemical structures of maribavir and several of its potential isomers are depicted in Figure 1 of the patent '632 Patent, FIG. 1
  • Technical Importance: This technical approach sought to resolve a previously unrecognized problem that may have caused a pivotal clinical trial to fail, thereby providing a path to improve or rescue the therapeutic utility of maribavir for treating CMV in vulnerable transplant patients '632 Patent, col. 2:20-40
• Key Claims at a Glance: The complaint alleges infringement of "one or more claims" Compl. ¶33 Independent claim 1 is representative:
  • A method for treatment of a herpes viral infection in a patient in need thereof
  • comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound,
  • in an amount of 400 mg twice a day,
  • wherein said patient is a stem cell transplant recipient.

U.S. Patent No. 12,213,989

• Patent Identification: U.S. Patent No. 12,213,989 (Use of Maribavir in Treatment Regimens), issued February 4, 2025.
• The Invention Explained:
  • Problem Addressed: The patent addresses the challenge of drug-drug interactions in transplant recipients, who often receive numerous other medications '989 Patent, col. 1:24-28 Specifically, it recognizes that drugs known as CYP3A4 inducers (e.g., certain anticonvulsants) can decrease the plasma concentration of maribavir, potentially leading to a reduced virologic response '989 Patent, col. 5:6-14
  • The Patented Solution: The invention provides specific methods for managing this drug-drug interaction by increasing the dosage of maribavir to counteract the effect of the CYP3A4 inducer '989 Patent, col. 6:15-24 For example, the patent claims a method of administering an elevated dose of 1200 mg of maribavir twice daily when a patient is also receiving the anticonvulsants phenytoin or phenobarbital '989 Patent, claim 1 The patent includes data from in vitro studies characterizing maribavir's interaction with the CYP3A enzyme '989 Patent, FIG. 1
  • Technical Importance: The invention provides specific, evidence-based dosing regimens that allow for the safe and effective co-administration of maribavir with other necessary medications, enhancing its utility in complex, polymedicated patient populations '989 Patent, col. 1:24-33
• Key Claims at a Glance: The complaint alleges infringement of "one or more claims" Compl. ¶42 Independent claim 1 is representative:
  • A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom,
  • the method comprising administering maribavir in an amount of 1200 mg orally twice daily,
  • wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,
  • wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.

Multi-Patent Capsules

• Patent Identification: U.S. Patent No. 12,295,940 (Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto), issued May 13, 2025.

• Technology Synopsis: The patent addresses shortcomings in prior art methods for synthesizing maribavir, such as low overall yield and the production of undesired byproducts '940 Patent, col. 1:55 - col. 2:8 It discloses an improved, five-step chemical synthesis process claimed to produce maribavir with a higher combined yield '940 Patent, abstract '940 Patent, col. 6:53-62

• Asserted Claims: "one or more claims" Compl. ¶51

• Accused Features: The complaint alleges statutory infringement based on Qilu's filing of an ANDA for a product containing maribavir Compl. ¶¶12; 51 The patent claims cover compositions of maribavir containing specific low levels of impurities that may result from the patented synthesis process.

• Patent Identification: U.S. Patent No. 12,433,907 (Use of Maribavir in Treatment Regimens), issued October 7, 2025.

• Technology Synopsis: This patent, related to the '989 Patent, addresses drug-drug interactions between maribavir and drugs that induce the CYP3A4 enzyme '907 Patent, col. 5:6-14 It provides methods for treating CMV infection that involve administering an increased dose of maribavir (e.g., 800 mg or 1200 mg twice daily) when co-administered with a CYP3A4 inducer to counteract the inducer's effect on maribavir plasma concentrations '907 Patent, col. 7:1-12

• Asserted Claims: "one or more claims" Compl. ¶60

• Accused Features: The complaint alleges statutory infringement based on Qilu's filing of an ANDA for a generic version of LIVTENCITY®, whose label instructs on dose adjustments when co-administered with CYP3A4 inducers Compl. ¶¶13; 60

• Patent Identification: U.S. Patent No. 12,447,169 (Maribavir Isomers, Compositions, Methods of Making and Methods of Using), issued October 21, 2025.

• Technology Synopsis: This patent, related to the '632 Patent, addresses the problem of maribavir's in vivo isomerization, which can reduce its efficacy '169 Patent, col. 1:56 - col. 2:19 The invention discloses methods for treating CMV infection by orally administering maribavir (400 mg twice a day) to transplant recipients, including specific instructions related to administration with or without food to mitigate the isomerization problem '169 Patent, claims 1-3

• Asserted Claims: "one or more claims" Compl. ¶69

• Accused Features: The complaint alleges statutory infringement based on Qilu's ANDA filing, as the proposed generic product is intended for the uses claimed in the patent, including the specified dosing regimens for transplant patients Compl. ¶¶12; 69

• Patent Identification: U.S. Patent No. 12,447,170 (Use of Maribavir in Treatment Regimens), issued October 21, 2025.

• Technology Synopsis: This patent, related to the '989 and '907 Patents, discloses methods for treating CMV infection in transplant recipients by administering maribavir at an increased dose (1200 mg orally twice daily) when the patient is concomitantly receiving an anticonvulsant like phenytoin or phenobarbital '170 Patent, claim 1 The invention also addresses interactions with immunosuppressants '170 Patent, col. 9:4-9

• Asserted Claims: "one or more claims" Compl. ¶78

• Accused Features: The complaint alleges statutory infringement via the ANDA filing, as the proposed generic product's labeling will instruct the specific dose-adjustment methods claimed in the patent Compl. ¶¶13; 78

III. The Accused Instrumentality

• Product Identification: Defendant Qilu's Abbreviated New Drug Application (ANDA) No. 221142 product ("Qilu's ANDA Product"), which is a generic version of LIVTENCITY® Compl. ¶¶27; 31
• Functionality and Market Context: The accused product is a 200 mg tablet of maribavir intended for oral administration Compl. ¶27 Maribavir is a cytomegalovirus (CMV) pUL97 kinase inhibitor Compl. ¶10 The product is indicated for the treatment of post-transplant CMV infection/disease that is refractory to treatment with other antiviral drugs Compl. ¶10 The complaint alleges that Qilu's product is intended to be a generic version of LIVTENCITY®, implying it will be sold for the same FDA-approved indications and with a substantially similar label Compl. ¶¶13; 31

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), where the filing of an ANDA for a drug claimed in a patent is a statutory act of infringement. The infringement theory is that the intended uses described in the defendant's proposed product labeling will direct or encourage users to perform the steps of the asserted method claims.

'632 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for treatment of a herpes viral infection in a patient in need thereof	Qilu's ANDA product is intended to be a generic version of LIVTENCITY®, which is indicated for the treatment of post-transplant CMV (a herpes virus) infection.	¶¶10; 31	col. 8:1-3
comprising orally administering to said patient the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer of said compound	Qilu's ANDA product comprises 200 mg tablets of maribavir for oral administration.	¶27	col. 8:4-8
in an amount of 400 mg twice a day	The FDA-approved labeling for LIVTENCITY®, which Qilu's generic labeling is intended to copy, instructs and encourages a dosing regimen of 400 mg twice a day.	¶13	col. 8:8-9
wherein said patient is a stem cell transplant recipient	LIVTENCITY® is indicated for use in post-transplant patients, which includes stem cell transplant recipients.	¶10	col. 8:10-11

• Identified Points of Contention:
  • Scope Questions: Claim 3 of the '632 patent recites administration "under fasted conditions." The patent specification extensively discusses isomerization as a problem occurring when the drug is taken with food '632 Patent, col. 2:40-56 A potential dispute is whether claims that do not explicitly recite "fasted conditions," like claim 1, should be interpreted as implicitly requiring them, which could impact infringement analysis for a product whose label allows administration with or without food.
  • Technical Questions: A key question for the court will be whether the evidence supports that Qilu's proposed product, simply by being a generic copy, will in fact be used according to the specific methods claimed, such as for the particular patient population of "stem cell transplant recipients."

'989 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating cytomegalovirus (CMV) infection in a patient suffering therefrom,	Qilu's ANDA product is a generic version of LIVTENCITY®, indicated for the treatment of CMV infection.	¶¶10; 31	col. 47:8-10
the method comprising administering maribavir in an amount of 1200 mg orally twice daily,	The FDA-approved labeling for LIVTENCITY®, which Qilu's generic label will copy, instructs physicians on dose adjustments, including an increase to 1200 mg twice daily when co-administered with certain drugs.	¶13	col. 47:11-12
wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital,	The intended use of the accused product is for post-transplant patients, who may be receiving concomitant medications including the specified anticonvulsants. The product label will instruct this specific use.	¶¶10; 13	col. 47:13-17
wherein maribavir is administered prior to, concurrently with, or subsequently from the administration of the anticonvulsant.	The proposed labeling for the generic product will instruct on the concomitant use of maribavir and the specified anticonvulsants.	¶13	col. 47:18-21

• Identified Points of Contention:
  • Scope Questions: A central issue may be whether Qilu's act of seeking approval for a generic drug with a label that describes a dose increase (in line with the LIVTENCITY® label) is sufficient to meet the "administering" step of the claim, which requires the actual performance of the method.
  • Legal Questions: The analysis of induced infringement will likely be a key battleground. The question will be whether Qilu's proposed label, by copying the branded drug's label, specifically encourages, recommends, or promotes the patented method of dose adjustment with enough specificity to establish the requisite intent for inducement.

V. Key Claim Terms for Construction

For U.S. Patent No. 11,684,632

• The Term: "under fasted conditions"
• Context and Importance: This term appears in dependent claim 3 but is central to the patent's core inventive concept of mitigating in vivo isomerization, which the specification links to administration with food '632 Patent, col. 2:40-56 Practitioners may focus on this term because its construction could influence the scope of all method claims, even those where the term is not explicit, under the doctrine of claim differentiation.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party could argue that because claim 1 does not recite this limitation while claim 3 does, claim 1 should not be limited to administration only under fasted conditions.
  • Evidence for a Narrower Interpretation: The specification provides a detailed definition: "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration of maribavir to at least about 1 to 3 hours after the administration" '632 Patent, col. 6:55-63 A party could argue this specific definition, tied to the patent's stated solution to the problem, should inform the scope of the method claims.

For U.S. Patent No. 12,213,989

• The Term: "administering maribavir in an amount of 1200 mg orally twice daily"
• Context and Importance: This term recites the specific, elevated dose that is the patent's proposed solution to the drug-drug interaction problem. Practitioners may focus on this term because the infringement dispute will likely center on whether Qilu, by marketing a generic drug with labeling that includes this dose as an option, can be held liable for inducing the "administering" step.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The plain language of "administering" refers to the act of giving the drug. Plaintiff will argue that by providing a drug with instructions for this specific dose in this specific scenario, Defendant is liable for the direct infringement that will inevitably result from following those instructions.
  • Evidence for a Narrower Interpretation: The specification details the clinical and in vitro data supporting this specific dose increase for specific inducers like phenytoin and phenobarbital '989 Patent, Example 2 '989 Patent, col. 7:1-12 A party may argue that infringement requires proof that the label actively and specifically encourages this non-standard, elevated dosage, rather than merely describing it as a possibility derived from the branded drug's studies.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all six patents-in-suit (Compl. ¶36; Compl. ¶37). The basis for inducement is the allegation that Defendant's proposed product labeling will instruct and encourage physicians and patients to use the generic drug in accordance with the patented methods Compl. ¶13 The basis for contributory infringement is the allegation that Defendant's product is especially adapted for infringing uses and lacks a substantial non-infringing use Compl. ¶37
• Willful Infringement: The complaint requests a finding that this is an "exceptional case" and an award of attorneys' fees under 35 U.S.C. § 285 for each asserted patent Compl. ¶40 Compl. ¶49 The factual basis for knowledge of the patents is Defendant's submission of an ANDA and its associated Paragraph IV certification, as well as the notice letter sent to Plaintiff Compl. ¶¶29-30 Compl. ¶38

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue for the '632 patent family will be one of infringement scope: Does the administration of a generic maribavir product, whose label permits dosing with or without food, constitute infringement of method claims rooted in solving the problem of isomerization that the patent specifically attributes to administration with food?
• A central question for the '989 patent family will be one of induced infringement: Does a generic drug manufacturer's proposed label, which is a copy of the branded drug's label and describes specific, elevated dosing regimens for managing drug-drug interactions, provide sufficient evidence of the specific intent required to find inducement of the patented methods?
• A key battleground for all asserted patents will likely be validity. The case may turn on whether the claimed methods of use-which involve specific dosages and patient populations-are found to be non-obvious over the prior art, particularly in a field where dose adjustments and managing drug interactions are arguably routine aspects of clinical practice.